trending Market Intelligence /marketintelligence/en/news-insights/trending/l_HTVZ2ng38GmdHyK691fA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

TG Therapeutics to raise $50M from stock offering to institutional investor

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

TG Therapeutics to raise $50M from stock offering to institutional investor

TG Therapeutics Inc. will raise about $50 million in gross proceeds from a public offering of its common stock to a single institutional investor.

The New York-based biopharmaceutical company agreed to sell about 5.4 million shares at $9.20 apiece to an undisclosed institutional investor with a biotechnology focus.

TG Therapeutics intends to use the proceeds from this offering for research and development, including development and commercialization of its lead drug candidates, ublituximab and umbralisib, and for general corporate purposes.

Gross proceeds from the offering will help the company end the year with about $140 million in cash and cash equivalents, said CEO Michael Weiss.

The offering is scheduled to close Dec. 23.

TG Therapeutics' umbralisib, which has received orphan drug and breakthrough therapy designations from the U.S. Food and Drug Administration, treats a type of blood cancer, while ublituximab treats multiple sclerosis.

In March, the company announced a stock offering and debt financing totaling $85 million to fund ongoing development of the two medicines.